Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD

1.27  +0.03 (+2.42%)

After market: 1.28 +0.01 (+0.79%)

Fundamental Rating

3

GERN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. GERN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GERN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

GERN had negative earnings in the past year.
GERN had a negative operating cash flow in the past year.
In the past 5 years GERN always reported negative net income.
In the past 5 years GERN always reported negative operating cash flow.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

GERN has a better Return On Assets (-29.40%) than 67.78% of its industry peers.
GERN has a Return On Equity (-62.28%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.4%
ROE -62.28%
ROIC N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

GERN has a better Gross Margin (98.37%) than 97.01% of its industry peers.
GERN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

4

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GERN has been increased compared to 1 year ago.
Compared to 5 years ago, GERN has more shares outstanding
GERN has a better debt/assets ratio than last year.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -2.65, we must say that GERN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GERN (-2.65) is comparable to the rest of the industry.
GERN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.42, GERN is doing worse than 73.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Altman-Z -2.65
ROIC/WACCN/A
WACC10.14%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

GERN has a Current Ratio of 5.56. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
GERN's Current ratio of 5.56 is fine compared to the rest of the industry. GERN outperforms 60.56% of its industry peers.
GERN has a Quick Ratio of 5.12. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
GERN has a Quick ratio (5.12) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.56
Quick Ratio 5.12
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.18% over the past year.
GERN shows a strong growth in Revenue. In the last year, the Revenue has grown by 32944.64%.
The Revenue has been growing by 178.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)32944.64%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%206586.96%

3.2 Future

Based on estimates for the next years, GERN will show a very strong growth in Earnings Per Share. The EPS will grow by 40.11% on average per year.
GERN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 65.75% yearly.
EPS Next Y60.54%
EPS Next 2Y43.92%
EPS Next 3Y40.2%
EPS Next 5Y40.11%
Revenue Next Year213.35%
Revenue Next 2Y122.15%
Revenue Next 3Y94.95%
Revenue Next 5Y65.75%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

GERN's earnings are expected to grow with 40.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.92%
EPS Next 3Y40.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GERN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GERON CORP

NASDAQ:GERN (4/17/2025, 8:24:28 PM)

After market: 1.28 +0.01 (+0.79%)

1.27

+0.03 (+2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners81.67%
Inst Owner Change0%
Ins Owners0.09%
Ins Owner Change15.63%
Market Cap808.88M
Analysts82.67
Price Target4.59 (261.42%)
Short Float %9.23%
Short Ratio3.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.24%
Min EPS beat(2)13.34%
Max EPS beat(2)53.15%
EPS beat(4)4
Avg EPS beat(4)20.54%
Min EPS beat(4)5.99%
Max EPS beat(4)53.15%
EPS beat(8)7
Avg EPS beat(8)17.98%
EPS beat(12)10
Avg EPS beat(12)16.88%
EPS beat(16)11
Avg EPS beat(16)11.76%
Revenue beat(2)2
Avg Revenue beat(2)23.92%
Min Revenue beat(2)2.07%
Max Revenue beat(2)45.76%
Revenue beat(4)4
Avg Revenue beat(4)342.15%
Min Revenue beat(4)2.07%
Max Revenue beat(4)1106.15%
Revenue beat(8)5
Avg Revenue beat(8)167.93%
Revenue beat(12)7
Avg Revenue beat(12)126.5%
Revenue beat(16)11
Avg Revenue beat(16)211.91%
PT rev (1m)0%
PT rev (3m)-40.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.72%
EPS NY rev (1m)-39.48%
EPS NY rev (3m)-23.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.51
P/FCF N/A
P/OCF N/A
P/B 2.89
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.12
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.4%
ROE -62.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.37%
FCFM N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.54%
Cap/Sales 0.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.56
Quick Ratio 5.12
Altman-Z -2.65
F-Score4
WACC10.14%
ROIC/WACCN/A
Cap/Depr(3y)153.53%
Cap/Depr(5y)161.21%
Cap/Sales(3y)140.92%
Cap/Sales(5y)119.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y60.54%
EPS Next 2Y43.92%
EPS Next 3Y40.2%
EPS Next 5Y40.11%
Revenue 1Y (TTM)32944.64%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%206586.96%
Revenue Next Year213.35%
Revenue Next 2Y122.15%
Revenue Next 3Y94.95%
Revenue Next 5Y65.75%
EBIT growth 1Y10.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year74.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.33%
OCF growth 3YN/A
OCF growth 5YN/A